Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation

Journal of Lipid Research

Volumn 40, Issue 11, 1999, Pages 2099-2110

  Raspe E ^a   Madsen, L ^c   Lefebvre, A M ^a   Leitersdorf, I ^a   Gelman, L ^a   Peinado Onsurbe, J ^d   Dallongeville, J ^a   Fruchart, J C ^a,b   Berge, R ^c   Staels, B ^a,b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b UNIV LILLE   (France)

^c UNIVERSITY OF BERGEN   (Norway)

^d NONE

Author keywords

3 thia fatty acids; Gene expression; Lipoprotein lipase; Lipoprotein metabolism; Peroxisome proliferator activated receptors

Indexed keywords

ACYL COENZYME A OXIDASE; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THIOACETIC ACID; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; EPIDIDYMIS FAT; FATTY ACID METABOLISM; GENE EXPRESSION REGULATION; LIPID BLOOD LEVEL; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; LIVER CELL; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN DOMAIN; RAT;

3T3 CELLS; ADIPOSE TISSUE; ANIMALS; APOLIPOPROTEINS; CELLS, CULTURED; FATTY ACIDS; GENE EXPRESSION REGULATION; HUMANS; LIPIDS; LIVER; MALE; MICE; PROTEIN ISOFORMS; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFIDES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0032740190     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Berge, R. K., and E. Hvattum. 1994. Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharmacol. Ther. 61: 345-383.
2. Aarsland, A., and R. Berge. 1990. Peroxisome proliferating sulphur- and oxysubstituted fatty acid analogues are activated to acyl coenzyme A thioesters. Biochem. Pharmacol. 41: 53-61.
3. Kryvi, H., A. Aarsland, and R. K. Berge. 1990. Morphologic effects of sulfur-substituted fatty acids on rat hepatocytes with special reference to proliferation of peroxisomes and mitochondria. J. Struct. Biol. 103: 257-265.
4. Skorve, J., D. Asiedu, A. Rustan, C. Drevon, A. Al-Shurbaji, and R. K. Berge. 1990. Regulation of fatty acid oxidation and triglyceride and phospolipid metabolism by hypolipidemic sulfur-substituted fatty acid analogues. J. Lipid Res. 31: 1627-1635.
5. Asiedu, D. K., A. Al-Shurbaji, A. C. Rustan, I. Björkhem, and R. K. Berge. 1995. Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids. Eur. J. Biochem. 227: 715-722.
6. Demoz, A., H. Vaagenes, N. Aarsaether, E. Hvattum, J. Skorve, M. Gottlicher, J. R. Lillehaug, G. G. Gibson, J. A. Gustafsson, S. Hood, and R. K. Berge. 1994. Coordinate induction of hepatic fatty acyl-CoA oxidase and P4504A1 in rat after activation of the peroxisome proliferator-activated receptor (PPAR) by sulfur-substituted fatty acid analogues. Xenobiotica. 24: 943-956.
7. Madsen, L., A. Garras, G. Asins, D. Serra, F. Hegardt, and R. K. Berge. 1999. Mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase and carnitine palmitoyltransferase II as potential control sites for ketogenesis during mitochondrion and peroxisome proliferation. Biochem. Pharmacol. 57: 1011-1019.
8. Madsen, L., and R. K. Berge. 1999. 3-Thia fatty acids treatment, in contrast to eicosapentaenoic acid and starvation, induces gene expression of carnitine palmitoyltransferase II in rat liver. Lipids. 34: 447-456.
9. Vaagenes, H., L. Madsen, D. K. Asiedu, J. R. Lillehaugh, and R. K. Berge. 1998. Early modulation of genes encoding peroxisomal and mitochondrial β-oxidation enzymes by 3-thia fatty acids. Biochem. Pharmacol. 56: 1571-1582.
10. Froyland, L., L. Madsen, W. Sjursen, A. Garras, L. Oyvind, J. Songstad, A. Rustan, and R. K. Berge. 1997. Effect of 3-thia fatty acids on the lipid composition of rat liver, lipoproteins and heart. J. Lipid Res. 38: 1522-1534.
11. Breslow, J. L. 1989. Familial disorders of high density lipoprotein metabolism. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. Vol I, 1251-1266.
12. Breslow, J. L. 1993. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc. Natl. Acad. Sci. USA. 90: 8314-8318.
13. Fruchart, J-C., and P. Duriez. 1998. High density lipoproteins and coronary heart disease. Future prospects in gene therapy. Biochimie. 80: 167-172.
14. Plump, A. S., S. K. Erickson, W. Weng, J. S. Partin, J. L. Breslow, and D. L. Williams. 1996. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J. Clin. Invest. 97: 2660-2671.
15. Schonfeld, G., P. I. Georges, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28: 1001-1009.
16. Stocks, J., G. Holdsworth, and D. J. Galton. 1979. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III. Lancet. ii: 667-671.
17. Le, N-A., J. C. Gibson, and H. N. Ginsberg. 1988. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J. Lipid Res. 29: 669-677.
18. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249: 790-793.
19. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
20. Goldberg, I. 1996. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37: 693-707.
21. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J-C. Fruchart. 1998. The mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093.
22. Staels, B., N. Vu-Dac, V. A. Kosykh, R. Saladin, J. C. Fruchart, J. Dallongeville, and J. Auwerx. 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J. Clin. Invest. 95: 705-712.
23. Staels, B., A. Van Tol, T. Andreu, and J. Auwerx. 1992. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12: 286-294.
24. Staels, B., A. van Tol, G. Verhoeven, and J. Auwerx. 1990. Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. Endocrinology. 126: 2153-2163.
25. Berthou, L., R. Saladin, P. Yaqoob, D. Branellec, P. Calder, J. C. Fruchart, P. Denefle, J. Auwerx, and B. Staels. 1995. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II, and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur. J. Biochem. 232: 179-187.
26. Schoonjans, K., J. Peinado-Onsurbe, A-M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348.
27. Krey, G., O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M. G. Parker, and W. Wahli. 1997. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11: 779-791.
28. Forman, B. M., J. Chen, and R. M. Evans. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA. 94: 4312-4317.
29. Staels, B., and J. Auwerx. 1997. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharmaceut. Des. 3: 1-14.
30. Kliewer, S. A., K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358: 771-774.
31. Keller, H., C. Dreyer, J. Medin, A. Mahfoudi, K. Ozato, and W. Wahli. 1993. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimcrs. Proc. Natl. Acad. Sci. USA. 90: 2160-2164.
32. Devchand, P. R., H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli. 1996. The PPARα-leukotriene B4 pathway to inflammation control. Nature. 384: 39-43.
33. Kliewer, S. A., J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehman. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83: 813-819.
34. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270: 12953-12956.
35. Forman, B. M., P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans. 1995. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83: 803-812.
36. Hertz, R., J. Bishara-Shieban, and J. Bar-Tana. 1995. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J. Biol. Chem. 270: 13470-13475.
37. Vu-Dac, N., K. Schoonjans, B. Laine, J. C. Fruchart, J. Auwerx, and B. Staels. 1994. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J. Biol. Chem. 269: 31012-31018.
38. Vu-Dac, N., K. Schoonjans, V. Kosykh, J. Dallongeville, J-C. Fruchart, B. Staels, and J. Auwerx. 1995. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 96: 741-750.
39. Peters, J. M., N. Hennuyer, B. Staels, J-C. Fruchart, C. Fievet, F. J. Gonzalez, and J. Auwerx. 1997. Alterations in lipoprotein metabolism in PPARα-deficient mice. J. Biol. Chem. 272: 27307-27312.
40. Lee, S. S., T. Pineau, J. Drago, E. J. Lee, J. W. Owens, D. L. Kroetz, P. M. Fernandez-Salguero, H. Westphal, and F. J. Gonzalez. 1995. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
41. Lefebvre, A-M., J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J-C. Fruchart, C. Fiévet, J. Auwerx, and B. Staels. 1997. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17: 1756-1764.
42. Spydevold, O., and J. Bremer. 1989. Induction of peroxisomal β-oxidation in 7800 Cl Morris hepatoma cells in steady state by fatty acids and fatty acid analogues. Biochim. Biophys. Acta. 1003: 72-79.
43. Berge, R. K., T. Flatmark, and H. Osmudsen. 1984. Enhancement of long-chain acyl-CoA hydrolase activity in peroxisomes and mitochondria of rat liver by peroxisomal proliferators. Eur. J. Biochem. 141: 637-644.
44. Willumsen, N., S. Hexeberg, J. Skorve, M. Lundquist, and R. K. Berge. 1993. Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. J. Lipid Res. 34: 13-22.
45. Bremer, J. 1981. The effect of fasting on the activity of liver carnitine palmitoyltransferase and its inhibition by malonyl-CoA. Biochim. Biophys. Acta. 665: 628-631.
46. Clinkenbeard, K. D., W. D. Reed, R. A. Mooney, and M. D. Lane. 1975. Intracellular localization of the 3-hydroxy-3-methylglutaryl CoA cycle enzymes in the liver. J. Biol. Chem. 250: 3108-3116.
47. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
48. Auwerx, J., S. Deeb, J. D. Brunzell, R. Peng, and A. C. Chait. 1988. Transcriptional activation of the lipoprotein lipase and apolipoprotein E genes accompanies differentiation in some human macrophage-like cell lines. Biochemistry. 27: 2651-2655.
49. Cleveland, D. W., M. A. Lopata, R. J. McDonald, M. J. Cowan, W. J. Rutter, and M. W. Kirschner. 1980. Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probes. Cell. 20: 95-105.
50. Masiakowski, P., R. Breathnach, J. Bloch, F. Gannon, A. Krust, and P. Chambon. 1982. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res. 10: 7895-7903.
51. Laborda, J. 1991. 36B4 cDNA used as an estradiol-independent mRNA control is the ellNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 19: 3998.
52. Esser, V., C. H. Britton, B. C. Weis, D. W. Foster, and J. D. McGarry. 1993. Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase I. J. Biol. Chem. 268: 5817-5822.
53. Asins, G., J. L. Rosa, D. Serra, G. Gil-Gomez, J. Ayté, R. Batrons, A. Tauler, and F. G. Hegardt. 1994. Gene expression of enzymes regulating ketogenesis and fatty acid metabolism in regenerating rat liver. Biochem. J. 299: 65-69.
54. Woeltje, K. F., V. Esser, B. C. Weis, A. Sen, W. F. Cox, M.J. McPhaul, C. A. Slaughter, D. W. Foster, and J. D. McGarry. 1990. Cloning, sequencing, and expression of a cDNA encoding rat liver mitochondrial carnitine palmitoyltransferase II. J. Biol. Chem. 265: 10720-10725.
55. Ayté, J., G. Gil-Gomez, D. Haro, P. F. Marrero, and F. G. Hegardt. 1990. Rat mitochondrial and cytosolic 3-hydroxy-3-methyglutaryl CoA synthases are encoded by two different genes. Proc. Natl. Acad. Sci. USA. 87: 3874-3878.
56. Luckow, B., and G. Schütz. 1987. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 15: 5490.
57. Webster, N., J. Jin, S. Green, M. Hollis, and P. Chambon. 1988. The yeast UASg is a transcriptional enhancer in human HeLa cells in the presence of the GAL4 trans-activator. Cell. 52: 169-178.
58. Fajas, L., D. Auboeuf, E. Raspé, K. Schoonjans, A-M. Lefebvre, R. Saladin, J. Najib, M. Laville, J-C. Fruchart, S. Deeb, A. Vidal-Puig, J. Flier, M. R. Briggs, B. Staels, H. Vidal, and J. Auwerx. 1997. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272: 18779-18789.
59. Gervois, P., I. P. Torra, G. Chinetti, T. Grotzinger, G. Dubois, J-C. Fruchart, J. Fruchart-Najib, E. Leitersdorf, and B. Staels. 1999. A truncated human peroxisome proliferator-activated receptor splice variant with dominant negative activity. Mol. Endocrinol. 13: 1535-1549.
60. Brewer, B., R. Gregg, J. Hoeg, and S. Fojo. 1988. Apolipoproteins and lipoproteins in human plasma: an overview. Clin. Chem. 34: B4-B8.
61. Beisiegel, U. 1998. Lipoprotein metabolism. Eur. Heart J. 19: A20-A23.
62. de Silva, H. V., S. J. Lauer, J. Wang, W. S. Simonet, K. H. Weisgraber, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269: 2324-2335.
63. Aalto-Setälä, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
64. Clavey, V., S. Lestavel-Delattre, C. Copin, J. M. Bard, and J. C. Fruchart. 1995. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler. Thromb. Vasc. Biol. 15: 963-971.
65. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apo C-III transgenic mice. J. Lipid Res. 37: 1802-1811.
66. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
67. McGarry, J. D., and D. W. Foster. 1980. Regulation of hepatic fatty acid oxidation and ketone body production. Annu. Rev. Biochem. 49: 395-420.
68. Asiedu, D., L. Froyland, H. Vaagenes, O. Lie, A. Demoz, and R. K. Berge. 1996. Long-term effect of tetradecylthioacetic acid: a study on plasma lipid profile and fatty acid composition and oxidation in different rat organs. Biochim. Biophys. Acta. 1300: 86-96.
69. Johnson, T., M. Holloway, R. Vogel, S. Rutledge, J. Perkins, G. Rodan, and A. Schmidt. 1997. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J. Steroid Biochem. Mol. Biol. 63: 1-8.
70. Torchia, J., C. Glass, and M. Rosenfeld. 1998. Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell. Biol. 10: 373-383.
71. Moras, D. 1998. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell. Biol. 10: 384-391.
72. Misiti, S., L. Schomburg, P. Yen, and W. Chin. 1998. Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology. 139: 2493-2500.